Skip to main content
Signal8
Launch Terminal

Lakefront Biotherapeutics NV (LKFT)

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lakefront Biotherapeutics N.V. logo

Lakefront Biotherapeutics N.V.

NASDAQ:LKFTHealthcare
-0.15%$32.28
AH$32.28+0.00%vs close
Mkt Cap$2.13B
Float65.9M
O/S65.9M
Vol
$ Vol
RVOL
Inst Own48.7%
SI2.1%
Earnings
Dilution
Lakefront Biotherapeutics N.V. logoNASDAQ:LKFT$32.28-0.15%
Phase Distribution
113 lead-sponsored trials·1 active·96 completed
Phase 173
Phase 1/21
Phase 233
Phase 36
(21 more as collaborator)
Status Overview
Recruiting1
Completed96
Stopped16

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

    Filgotinib

    Crohn's Disease

    Enrollment
    1,372
    Start
    Oct 2016
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT02914561
  • Phase 3
    Terminated

    Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

    Filgotinib, Placebo

    Crohn's Disease

    Enrollment
    1,188
    Start
    Mar 2017
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT02914600
  • Phase 3
    Terminated

    A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

    GLPG1690, Placebo

    Idiopathic Pulmonary Fibrosis

    Enrollment
    525
    Start
    Nov 2018
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT03711162
  • Phase 3
    Terminated

    A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

    GLPG1690, Placebo

    Idiopathic Pulmonary Fibrosis

    Enrollment
    781
    Start
    Nov 2018
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT03733444
  • Phase 3
    Terminated

    A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

    Filgotinib, Placebo

    Ulcerative Colitis

    Enrollment
    22
    Start
    Jul 2022
    Primary Completion
    Oct 2023
    Completion
    Oct 2023
    NCT05479058
  • Phase 3
    Recruiting

    Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

    GLPG CAR T-cell therapy

    Hematological Malignancies

    Enrollment
    546
    Start
    Sep 2024
    Primary Completion
    Jul 2039est.
    Completion
    Jul 2039est.
    NCT06652633
  • Phase 2
    Terminated

    Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

    PEG-liposomal prednisolone sodium phosphate, Methylprednisolone

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome

    Enrollment
    15
    Start
    Dec 2009
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT01039103
  • Phase 2
    Completed

    GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

    GLPG0259 oral capsule, Placebo

    Rheumatoid Arthritis

    Enrollment
    30
    Start
    Oct 2010
    Primary Completion
    Apr 2011
    Completion
    Apr 2011
    NCT01211249
  • Phase 2
    Completed

    Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

    GLPG0634

    Rheumatoid Arthritis

    Enrollment
    36
    Start
    Jun 2011
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT01384422
  • Phase 2
    Completed

    Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

    GLPG0634, Placebo

    Rheumatoid Arthritis

    Enrollment
    91
    Start
    May 2012
    Primary Completion
    Sep 2012
    Completion
    Oct 2012
    NCT01668641
  • Phase 2
    Completed

    Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

    GLPG0974, Placebo

    Ulcerative Colitis

    Enrollment
    45
    Start
    Apr 2013
    Primary Completion
    Apr 2014
    Completion
    Apr 2014
    NCT01829321
  • Phase 2
    Completed

    Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

    GLPG0634, Placebo

    Rheumatoid Arthritis

    Enrollment
    599
    Start
    Jul 2013
    Primary Completion
    Feb 2015
    Completion
    May 2015
    NCT01888874
  • Phase 2
    Completed

    Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

    GLPG0634, Placebo

    Rheumatoid Arthritis

    Enrollment
    287
    Start
    Oct 2013
    Primary Completion
    Mar 2015
    Completion
    May 2015
    NCT01894516
  • Phase 2
    Completed

    Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

    GLPG0634, Placebo

    Crohn's Disease

    Enrollment
    175
    Start
    Feb 2014
    Primary Completion
    Nov 2015
    Completion
    Feb 2016
    NCT02048618
  • Phase 2
    Completed

    Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

    Filgotinib

    Rheumatoid Arthritis

    Enrollment
    739
    Start
    Feb 2014
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT02065700
  • Phase 2
    Completed

    Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

    GLPG1205, Placebo

    Ulcerative Colitis

    Enrollment
    64
    Start
    Dec 2014
    Primary Completion
    Sep 2015
    Completion
    Nov 2015
    NCT02337608
  • Phase 2
    Completed

    Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)

    GLPG1837 dose 1, GLPG1837 dose 2

    Cystic Fibrosis

    Enrollment
    7
    Start
    Jan 2016
    Primary Completion
    Aug 2016
    Completion
    Sep 2016
    NCT02690519
  • Phase 2
    Completed

    Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

    GLPG1837 dose 1, GLPG1837 dose 2

    Cystic Fibrosis

    Enrollment
    26
    Start
    Feb 2016
    Primary Completion
    Nov 2016
    Completion
    Nov 2016
    NCT02707562
  • Phase 2
    Completed

    Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

    GLPG1690 600 mg QD, Placebo QD

    Idiopathic Pulmonary Fibrosis

    Enrollment
    23
    Start
    Mar 2016
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT02738801
  • Phase 2
    Completed

    A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

    GLPG2222 150 mg q.d., GLPG2222 300 mg q.d.

    Cystic Fibrosis

    Enrollment
    37
    Start
    Jan 2017
    Primary Completion
    Aug 2017
    Completion
    Aug 2017
    NCT03045523
  • Phase 2
    Completed

    A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis

    filgotinib, Placebo Oral Tablet

    Psoriatic Arthritis

    Enrollment
    131
    Start
    Mar 2017
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT03101670
  • Phase 2
    Completed

    A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

    filgotinib, Placebo Oral Tablet

    Ankylosing Spondylitis

    Enrollment
    116
    Start
    Mar 2017
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03117270
  • Phase 2
    Completed

    A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

    GLPG2222 50 mg, GLPG2222 100 mg

    Cystic Fibrosis

    Enrollment
    59
    Start
    Mar 2017
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT03119649
  • Phase 2
    Terminated

    Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

    Filgotinib, Placebo

    Inflammatory Bowel Disease

    Enrollment
    139
    Start
    Jul 2017
    Primary Completion
    Nov 2020
    Completion
    Oct 2023
    NCT03201445
  • Phase 2
    Terminated

    An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

    filgotinib

    Psoriatic Arthritis

    Enrollment
    122
    Start
    Jul 2017
    Primary Completion
    Jun 2021
    Completion
    Jun 2021
    NCT03320876

1-25 of 113

Search ClinicalTrials.gov for “Lakefront Biotherapeutics”